Investing.com - Amneal Pharma A (NYSE: AMRX) reported second quarter EPS of $0.190, $0.09 better than the analyst estimate of $0.100. Revenue for the quarter came in at $599M versus the consensus estimate of $565.11M.
Guidance
Amneal Pharma A sees FY 2023 EPS of $0.450-$0.550 versus the analyst consensus of $0.470.
Amneal Pharma A sees FY 2023 revenue of $2.300B-$2.400B versus the analyst consensus of $2.320B.
Amneal Pharma A's stock price closed at $3.360. It is up 75.000% in the last 3 months and up 5.660% in the last 12 months.
Amneal Pharma A saw 1 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Amneal Pharma A's stock price’s past reactions to earnings here.
According to InvestingPro, Amneal Pharma A's Financial Health score is "good performance".
Check out Amneal Pharma A's recent earnings performance, and Amneal Pharma A's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar